Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biogaia Adr Class B BIOGY

Healthcare Biotechnology
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics... see more

Recent & Breaking News (PINL:BIOGY)

Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-HPV in Combination With MedImmune's MEDI4736 for the Treatment of HPV-Associated Cancers

GlobeNewswire December 15, 2014

CNH Industrial and Evogene Subsidiary Announce Ongoing Collaboration for the Development of a Mechanized Harvesting Solution for Castor Beans

GlobeNewswire December 15, 2014

DELCATH STRENGTHENS BOARD OF DIRECTORS WITH NEW APPOINTMENTS

Thomson Reuters ONE December 15, 2014

Ignyta Announces Amendment to License Agreement with Nerviano

Business Wire December 15, 2014

Yumanity Therapeutics Launched by Tony Coles, M.D. to Identify and Develop New Therapies for Neurodegenerative Diseases Caused by Protein Misfolding

Business Wire December 15, 2014

Insmed Provides End of Year Regulatory and Clinical Update

Business Wire December 15, 2014

Bruker Introduces BioScope Resolve High-Resolution BioAFM System

Business Wire December 15, 2014

Sucampo Appoints John H. Johnson to Board of Directors

GlobeNewswire December 15, 2014

BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office

PR Newswire December 15, 2014

China Green Agriculture to Hold a National Distributor Conference in Xi'an

PR Newswire December 15, 2014

CNH Industrial and Evogene Subsidiary Announce Ongoing Collaboration for the Development of a Mechanised Harvesting Solution for Castor Beans

PR Newswire December 15, 2014

Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015

PR Newswire December 15, 2014

PAREXEL ClinPhone® RTSM Named Leader Of Interactive Response Technology In New Benchmark Report From Industry Standard Research

PR Newswire December 15, 2014

TrendForce: 2015 Worldwide Solar Demand to Grow 16.5%, Emerging Markets Growth to Surpass 40%

PR Newswire December 15, 2014

NetScientific plc: NetScientific Invests in Next Generation, Immunotherapeutics Company, PDS Biotechnology

Business Wire December 15, 2014

VECT-HORUS: new equity issue of 1.5 MEU to finance the preclinical development of its first vectorized product

GlobeNewswire December 15, 2014

VECT-HORUS: new equity issue of 1.5 MEuro to finance the preclinical development of its first vectorized product

Thomson Reuters ONE December 15, 2014

Exelixis' Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and Vemurafenib for the Treatment of Patients With BRAF V600 Mutation-Positive Advanced Melanoma

Business Wire December 15, 2014

Genentech Submits New Drug Application to FDA for Investigational Cobimetinib Used in Combination With Zelboraf (vemurafenib) in Advanced Melanoma

Business Wire December 15, 2014

Roche expands CE-IVD claims for organ and tissue testing for next generation blood screening assays

PR Newswire December 15, 2014